Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension

Chest

Volumn 139, Issue 1, 2011, Pages 109-114

  Cartin Ceba, Rodrigo ^a   Swanson, Karen ^a   Iyer, Vivek ^a   Wiesner, Russell H ^a   Krowka, Michael J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN;

ADULT; ADVANCED CANCER; ARTICLE; BUDD CHIARI SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; END STAGE LIVER DISEASE; FEMALE; HEART CATHETERIZATION; HUMAN; INTRAOCULAR HEMORRHAGE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; OPTIMAL DRUG DOSE; PERIPHERAL EDEMA; PORTAL VEIN THROMBOSIS; PORTOPULMONARY HYPERTENSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPTIC SHOCK; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 78651428145     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-0574     Document Type: Article

References (22)

1. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology. 1999;30(3):641-648. (Pubitemid 29409407)
2. Le Pavec J, Souza R, Herve P, et al. Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med. 2008;178(6):637-643.
3. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S43-S54.
4. Benjaminov FS, Prentice M, Sniderman KW, Siu S, Liu P, Wong F. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut. 2003;52(9):1355-1362. (Pubitemid 37026471)
5. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl. 2000;6(4):443-450.
6. Krowka MJ, Mandell MS, Ramsay MA, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl. 2004 ;10(2):174-182.
7. Mandall MS, Krowka MJ. Formation of a national database on pulmonary hypertension and hepatopulmonary syndrome in chronic liver disease. Anesthesiology. 1997;87(2):450-451.
8. Krowka MJ. Evolving dilemmas and management of portopulmonary hypertension. Semin Liver Dis. 2006;26(3):265-272.
9. Budhiraja R, Hassoun PM. Portopulmonary hypertension: a tale of two circulations. Chest. 2003;123(2):562-576. (Pubitemid 36269445)
10. Barth F, Gerber PJ, Reichen J, Dufour JF, Nicod LP. Efficiency and safety of bosentan in child C cirrhosis with portopulmonary hypertension and renal insufficiency. Eur J Gastroenterol Hepatol. 2006;18(10):1117-1119. (Pubitemid 44379366)
11. Kim WR, Krowka MJ, Plevak DJ, et al. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl. 2000;6(4):453-458.
12. Swanson KL, Wiesner RH, Nyberg SL, Rosen CB, Krowka MJ. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant. 2008;8(11):2445-2453.
13. Opitz CF, Ewert R, Kirch W, Pittrow D. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J. 2008;29(16):1936-1948.
14. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896-903.
15. Hinterhuber L, Graziadei IW, Kähler CM, Jaschke W, Vogel W. Endothelin-receptor antagonist treatment of portopulmonary hypertension. Clin Gastroenterol Hepatol. 2004;2(11):1039-1042. (Pubitemid 39539755)
16. Kuntzen C, Gülberg V, Gerbes AL. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy? Gastroenterology. 2005;128(1):164-168. (Pubitemid 40039967)
17. Halank M, Miehlke S, Hoeffken G, Schmeisser A, Schulze M, Strasser RH. Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension. Transplantation. 2004;77(11):1775-1776. (Pubitemid 38780551)
18. Grander W, Eller P, Fuschelberger R, Tilg H. Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C. Eur J Clin Invest. 2006;36(Suppl 3):67-70.
19. Hoeper MM, Seyfarth HJ, Hoeffken G, et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J. 2007;30(6):1096-1102.
20. Hoeper MM, Halank M, Marx C, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J. 2005;25(3):502-508.
21. Croxtall JD, Keam SJ. Ambrisentan. Drugs. 2008;68(15):2195-2204.
22. Galiè N, Olschewski H, Oudiz RJ, et al; Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2. Circulation. 2008;117(23):3010- 3019.